THE FIRST EXPERIENCE IN USING TENOFOVIR TO TREAT HIV-INFECTED PATIENTS IN RUSSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To preliminarily evaluate the efficacy and safety of tenofovir disoproxil furamate (TDF) clinically used in combination with lamivudine (3TC) as the nucleoside base of an antiretroviral therapy (ARVT) in Russia. Materials and methods. The results obtained at 24 weeks of therapy in 45 HIV-infected patients on the ARTV comprising the nucleoside base including RDF (Hetero Drugs Limited, India) in combination with 3TC were summarized. Efavirenz (EFV), lopinavir/ritonavir (LOV/r), ritonavir-boosted atazanavir (ATV/r), or raltegravir (RAL) was included as the third agent in the ARVTregimen. Nineteen patients (Group 1) had not received ARVT before and 26 patients (Group 2) had already been on other treatment regimens. The data were statistically processed using non-parametric methods. Results. Group 1 showed: a reduction in blood HIV RNA levels in all the patients (the undetectable level of this indicator was achieved in 26% of the patients after 4-week treatment, in 50% after 12 weeks, and in 72% of the those who had completed the study following 24 weeks; the level of below 1000 copies/ml was achieved in 58, 94, and 100% in these periods, respectively); a rise of 24-week treatment CD4 lymphocyte counts per 106 cells/μl versus the baseline and per 142 cells/μl versus the expected level in the natural history of the disease; an increase in 24-week treatment median blood platelet counts per 25 billion/l (from 154 to 179 billion/l), the minimal value rose from 26 to 109 billin/l. When switched to the regimens involving a combination of TDF and 3TC as the nucleoside base, Group 2 displayed: no increase in blood HIVRNA levels and maintenance of its previously achieved undetectable level; no decrease in CD4 lymphocyte counts (the recorded increase by 37cells/μl at 24 weeks of a new treatment regimen was statistically insignificant). There was no clinical progression of HIV infection or adverse reactions due to TDF use in both groups. Conclusion. 24-week ARV Tregimens including TDS + 3TC as the nucleoside base was efficacious and safe in both groups.

Full Text

Restricted Access

About the authors

Oleg G. Yurin

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: oleg_gerald@mail.ru
Moscow

M. D Goliusova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: mad2501@yandex.ru
Moscow

M. O Deulina

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: de-marik@yandex.ru
Moscow

N. V Kozyrina

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: nad-kozyrina@yandex.ru
Moscow

V. V Konnov

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: konnov.vlad@gmail.com
Moscow

P. S Narsia

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: narsia@hivrussia.net
Moscow

T. V Buravtsova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: buravtsova@hivrussia.net
Moscow

O. S Efremova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: ks517@yandex.ru
Moscow

L. A Ivanova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: iwanova.larisa@yandex.ru
Moscow

R. V Ivannikova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: rivannikova@yandex.ru
Moscow

D. S Konnov

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: kodanila@yandex.ru
Moscow

U. A Kuimova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: ula-girl@mail.ru
Moscow

A. V Pokrovskaya

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: pokrovskaya_av@mail.ru
Moscow

A. A Popova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: asya-med@mail.ru
Moscow

L. V Serebrovskaya

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: serebrovskaja@yandex.ru
Moscow

Z. K Suvorova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: zksu@inbox.ru
Moscow

V. V Pokrovsky

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: pokrovsky@hivrussia.net
Moscow

References

  1. Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. М.: Р. Валент, 2012. 528 с.
  2. ВИЧ-инфекция и СПИД. Клинич. рекомендации. Под ред. В.В. Покровского. М.: ГЭОТАР-Медиа, 2010.
  3. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2011. Available from http://www.hivbook.com.
  4. Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Национальное научное общество инфекционистов. Эпидемиол. инфекц. болезни. Актуал. вопр. 2012; 6, приложение. 27 с.
  5. Обследование и антиретровирусная терапия у взрослых и подростков: Клинический протокол для Европейского региона ВОЗ (обновленная версия 2011 г.). Под ред. Jens Lundgren, Lars Peters, Irina Eramova. Копенгаген: ВОЗ, 2011.
  6. Keiser O., Fellay J., Opravil. M. et al. Adverse events to antiretrirals in Swiss HIV Cohort Study: effect of mortality and treatment modification. Antivir. Ther. 2007; 12(8): 1157-1164.
  7. Koka P.S., Reddy S.T. Cytopenias in HIV infection: mechanisms and alleviation of hematopoietic inhibition. Curr. HIV Res. 2004; 2: 275-282.
  8. Levine А.М., Scadden D.T., Zaia J.A. et al. Hematologic aspects of HIV/AIDS. Hematology 2001; 2: 463-478.
  9. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2012. 4th February 2012. Available from http: //www.bhiva. org
  10. Guidelines for the clinical management and treatment of HIV-infected adults in Europe (Version 6,0; October 2011). European AIDS Clinical Society (http://www. europeanaidsclinicalsociety.org).
  11. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS) March 27, 2012. Available from http://www.AIDSinfo.nih.gov.
  12. Thompson M.A., Aberg J.A., Hoy J.F. et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AIDS Society-USA panel. JAMA 2012; 308(4): 387-402.
  13. McCune J.M. The dynamycs of CD4+ T-cell depletion in HIV disease. Nature 2001; 410: 974-979.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies